Patents by Inventor Rachid Lani
Rachid Lani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11946041Abstract: The invention relates to a method for screening a library of peptide ligands, said library comprising a plurality of polypeptides covalently linked to a molecular scaffold at two or more amino acid residues, comprising the steps of displaying said library of peptide ligands in a genetic display system, wherein the polypeptide comprises two or more reactive groups which form a covalent linkage to the molecular scaffold, and at least one loop which comprises a sequence of amino acids subtended between two of said reactive groups; exposing the peptide ligands to one or more cells which display one or more target molecules on the cell surface; and screening the peptide ligands for binding against the target, and selecting the ligands which bind to the target.Type: GrantFiled: April 24, 2018Date of Patent: April 2, 2024Assignee: BicycleRD LimitedInventors: Liuhong Chen, Michael Skynner, Amy Brown, James Cooke, Rachid Lani
-
Publication number: 20230220008Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: ApplicationFiled: November 14, 2022Publication date: July 13, 2023Inventors: Liuhong CHEN, Rachid LANI, Kevin MCDONNELL, Gemma MUDD, Peter U. PARK, Punit UPADHYAYA
-
Patent number: 11542304Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: GrantFiled: October 26, 2020Date of Patent: January 3, 2023Inventors: Liuhong Chen, Rachid Lani, Kevin Mcdonnell, Gemma Mudd, Peter U. Park, Punit Upadhyaya
-
Publication number: 20220213145Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: ApplicationFiled: January 21, 2022Publication date: July 7, 2022Inventors: Liuhong CHEN, Rachid LANI, Kevin MCDONNELL, Gemma Elizabeth MUDD, Peter PARK
-
Publication number: 20220133732Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of carbonic anhydrase IX (CAIX).The invention also includes dmg conjugates comprising said peptides,conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CAIX.Type: ApplicationFiled: January 15, 2020Publication date: May 5, 2022Inventors: Leonardo BALDASSARRE, Liuhong CHEN, Rachid LANI, Catherine STACE, Daniel TEUFEL, Edward WALKER
-
Publication number: 20220133733Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD38. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD38.Type: ApplicationFiled: January 15, 2020Publication date: May 5, 2022Inventors: Leonardo BALDASSARRE, Rachid LANI, Silvia PAVAN, Catherine STACE, Daniel TEUFEL
-
Publication number: 20220119488Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of integrin ?v?3.The invention also includes drug conjugates comprising said peptides,conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and dmg conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by integrin ?v?3.Type: ApplicationFiled: January 15, 2020Publication date: April 21, 2022Inventors: Rachid LANI, Catherine STACE, Daniel TEUFEL, Edward WALKER
-
Publication number: 20220088118Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of carbonic anhydrase IX (CAIX). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CAIX.Type: ApplicationFiled: January 15, 2020Publication date: March 24, 2022Inventors: Leonardo BALDASSARRE, Liuhong CHEN, Rachid LANI, Catherine STACE, Daniel TEUFEL, Edward WALKER
-
Publication number: 20220064221Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of integrin ?v?3. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by integrin ?v?3.Type: ApplicationFiled: January 15, 2020Publication date: March 3, 2022Inventors: Rachid LANI, Catherine STACE, Daniel TEUFEL, Edward WALKER
-
Publication number: 20220064218Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD38.The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and dmg conjugates in preventing, suppressing or treating a disease or disorder mediated by CD38.Type: ApplicationFiled: January 15, 2020Publication date: March 3, 2022Inventors: Leonardo BALDASSARRE, Rachid LANI, Silvia PAVAN, Catherine STACE, Daniel TEUFEL
-
Patent number: 11261214Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: GrantFiled: August 3, 2018Date of Patent: March 1, 2022Assignee: BicycleTx LimitedInventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Mudd, Peter Park
-
Publication number: 20220024983Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of IL-17. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by IL-17.Type: ApplicationFiled: December 13, 2019Publication date: January 27, 2022Inventors: Liuhong CHEN, Rachid LANI, Gemma MUDD, Daniel TEUFEL, Edward WALKER
-
Publication number: 20220024982Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.Type: ApplicationFiled: December 13, 2019Publication date: January 27, 2022Inventors: Liuhong CHEN, Euan RICHARDS, Rachid LANI, Gemma MUDD, Catherine STACE, Daniel TEUFEL, Edward WALKER
-
Publication number: 20210101933Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: ApplicationFiled: October 26, 2020Publication date: April 8, 2021Inventors: Liuhong CHEN, Rachid LANI, Kevin MCDONNELL, Gemma MUDD, Peter U. PARK, Punit UPADHYAYA
-
Publication number: 20200407709Abstract: The invention relates to a method for screening a library of peptide ligands, said library comprising a plurality of polypeptides covalently linked to a molecular scaffold at two or more amino acid residues, comprising the steps of displaying said library of peptide ligands in a genetic display system, wherein the polypeptide comprises two or more reactive groups which form a covalent linkage to the molecular scaffold, and at least one loop which comprises a sequence of amino acids subtended between two of said reactive groups; exposing the peptide ligands to one or more cells which display one or more target molecules on the cell surface; and screening the peptide ligands for binding against the target, and selecting the ligands which bind to the target.Type: ApplicationFiled: April 24, 2018Publication date: December 31, 2020Inventors: Liuhong Chen, Michael Skynner, Amy Brown, James Cooke, Rachid Lani
-
Patent number: 10875894Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: GrantFiled: February 22, 2019Date of Patent: December 29, 2020Assignee: BicycleTx LimitedInventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Elizabeth Mudd, Peter U. Park, Punit Upadhyaya
-
Publication number: 20200255477Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: ApplicationFiled: August 3, 2018Publication date: August 13, 2020Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Mudd, Peter Park
-
Publication number: 20190263866Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: ApplicationFiled: February 22, 2019Publication date: August 29, 2019Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Elizabeth Mudd, Peter U. Park, Punit Upadhyaya